The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.
 
Stephanie Leigh Alden
No Relationships to Disclose
 
Mir Lim
No Relationships to Disclose
 
Chester Kao
No Relationships to Disclose
 
Daniel Shu
No Relationships to Disclose
 
Amit G. Singal
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Exact Sciences; Exelixis; Genentech; Glycotest; Roche; Target Pharmasolutions; Wako Diagnostics
Research Funding - Abbvie (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Eisai; Exelixis
 
Anne M. Noonan
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I); Deciphera (I); Eisai; Exelixis; GOG Foundation (I); Helsinn Healthcare; Immunogen (I); Merck (I); OncLive/MJH Life Sciences; OncLive/MJH Life Sciences (I); QED Therapeutics
 
Paige Griffith
Consulting or Advisory Role - Eisai/H3 Biomedicine; Exelixis
Travel, Accommodations, Expenses - Helsinn Therapeutics
 
Marina Baretti
No Relationships to Disclose
 
Won Jin Ho
Honoraria - Standard Biotools
Consulting or Advisory Role - Exelixis
Research Funding - NeoTX (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - I hold patents and receive royalties from Rodeo Therapeutics.
 
Ihab R. Kamel
Research Funding - Siemens Healthineers
 
Mark Yarchoan
Leadership - Adventris Pharmaceuticals
Stock and Other Ownership Interests - Adventris Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Genentech/Roche; Hepion Pharmaceuticals; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Incyte (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Merck
 
David Hsiehchen
No Relationships to Disclose